Persistent Bone Marrow Minimal Residual Disease is a Poor Prognostic Marker for Neuroblastoma

被引：0
|
作者：
Feng, C. [1 ]
Li, Y. [1 ]
Wu, P. [1 ]
Xiong, X. [1 ]
Peng, X. [1 ]
Weng, W. [1 ]
机构：
[1] Sun Yat Sen Mem Hosp, Pediat Hematol Oncol, Guangzhou, Guangdong, Peoples R China
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO130 SIOP
引用
收藏
页码：S605 / S606
页数：2
相关论文
共 50 条
  • [31] Expression Profiles of Seven Minimal Residual Disease Markers in Bone Marrow and Peripheral Blood of Patients with High-Risk Neuroblastoma
    Nishimura, N.
    Thwin, K. K. M.
    Ishida, T.
    Uemura, S.
    Yamamoto, N.
    Tamura, A.
    Kozaki, A.
    Saito, A.
    Kishimoto, K.
    Hasegawa, D.
    Kosaka, Y.
    Nino, N.
    Takafuji, S.
    Mori, T.
    Iijima, K.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S268 - S268
  • [32] EARLY MOLECULAR RESPONSE OF BONE MARROW DISEASE IS HIGHLY PROGNOSTIC FOR SURVIVAL IN NEUROBLASTOMA
    Stutterheim, Janine
    Zappeij-Kannegieter, Lily
    Caron, Huib N.
    Schoot, C. Ellen
    Tytgat, Godelieve A. M.
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 736 - 736
  • [33] Dynamics of Minimal Residual Disease in Neuroblastoma Patients
    Uemura, Suguru
    Ishida, Toshiaki
    Thwin, Khin Kyae Mon
    Yamamoto, Nobuyuki
    Tamura, Akihiro
    Kishimoto, Kenji
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    Nino, Nanako
    Lin, Kyaw San
    Takafuji, Satoru
    Mori, Takeshi
    Iijima, Kazumoto
    Nishimura, Noriyuki
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [34] BONE-MARROW TRANSPLANTATION FOR POOR PROGNOSIS NEUROBLASTOMA
    SEEGER, RC
    WELLS, J
    LENARSKY, C
    FEIG, SA
    SELCH, M
    MOSS, TJ
    UGELSTAD, J
    REYNOLDS, CP
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 215 - 215
  • [35] Minimal residual disease in neuroblastoma:: To GAGE or not to GAGE
    Oltra, S
    Martínez, F
    Orellana, C
    Grau, E
    Fernández, JM
    Cañete, A
    Castel, V
    ONCOLOGY RESEARCH, 2004, 14 (06) : 291 - 295
  • [36] Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma
    Bai, Yinlei
    Chim, Chor Sang
    HEMATOLOGY, 2019, 24 (01) : 533 - 537
  • [37] PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma
    Stutterheim, Janine
    Gerritsen, Annemieke
    Zappeij-Kannegieter, Lily
    Kleijn, Ilona
    Dee, Rob
    Hooft, Lotty
    van Noesel, Max M.
    Bierings, Marc
    Berthold, Frank
    Versteeg, Rogier
    Caron, Huib N.
    van der Schoot, C. Ellen
    Tytgat, Godelieve A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5443 - 5449
  • [38] Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma
    Cheung, Irene Y.
    Feng, Yi
    Vickers, Andrew
    Gerald, William
    Cheung, Nai-Kong V.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2007, 9 (02): : 237 - 241
  • [39] Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeuctic Target in Neuroblastoma
    Roderwieser, Andrea
    Sand, Frederik
    Walter, Esther
    Fischer, Janina
    Gecht, Judith
    Bartenhagen, Christoph
    Ackermann, Sandra
    Otte, Felix
    Welte, Anne
    Kahlert, Yvonne
    Lieberz, Daniela
    Hertwig, Falk
    Reinhardt, H. Christian
    Simon, Thorsten
    Peifer, Martin
    Ortmann, Monika
    Buettner, Reinhard
    Hero, Barbara
    O'Sullivan, Roderick J.
    Berthold, Frank
    Fischer, Matthias
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 20
  • [40] Monitoring minimal residual disease in the bone marrow using next generation sequencing
    Rustad, Even H.
    Boyle, Eileen M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2020, 33 (01)
12345